Alnylam Pharmaceuticals reported 13.17 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amgen 18.6 0.53 Sep/2026
Arrowhead Research 39.19 0 Jun/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novartis 21.54 0.18 Sep/2026
PTC Therapeutics 8.76 0 Jun/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Sanofi 21.74 11.35 Sep/2026
Sarepta Therapeutics 32.09 22.66 Sep/2026
Takeda 21.04 3.36 Sep/2026
Tectonic Therapeutic 4.01 0.63 Mar/2024
Vertex Pharmaceuticals 29.35 1.3 Sep/2026
Xencor 29.92 3.22 Sep/2022